Background
==========

The angiotensin-converting enzyme (ACE), a key enzyme in the renin-angiotensin system, plays the important roles of regulating of blood pressure and serum electrolytes \[[@B1],[@B2]\]. It has also been implicated in the pathogenesis of several cancers, such as lung cancer, breast cancer, prostate cancer, gastric cancer and oral cancer \[[@B2]-[@B6]\]. It is differentially expressed in several carcinomas and may affect tumor cell proliferation, migration, angiogenesis, and metastatic behaviors \[[@B7]\]. Inhibition of ACE activity suppresses tumor growth and angiogenesis in vitro and vivo of animal models; moreover, epidemiologic studies have also indicated that ACE inhibitors might decrease the risk and mortality rate of cancers \[[@B2],[@B7]\].

The human *ACE*gene is located on chromosome 17q23, and many polymorphisms have been identified \[[@B8]\]. The most widely studied polymorphism Insertion/Deletion (I/D, rs4646994) is located on intron 16\[[@B6]\]. It is characterized by the presence or absence of a 287-bp Alu repetitive sequence, which results in three genotypes: II, DI and DD \[[@B6]\]. The I/D polymorphism accounts for 20% to 50% of the variance in *ACE*expression or activity in blood and tissues among individuals \[[@B7]\]. Homozygote II may display as low as half of the plasma ACE level compared to the homozygote DD, whereas the heterozygote DI displays an intermediate level\[[@B2]\]. Recently, many studies investigated the role of this polymorphism in the etiology of cancers among various organs, including lung, breast, prostate, gastric, oral and others \[[@B3]-[@B7],[@B9]-[@B18]\]. However, the observed associations of these studies were inconsistent, and a single study might be insufficient to detect a possible small effect of the polymorphism on cancers. Meta-analysis is a useful method for investigating the associations between diseases and risk factors because it uses a quantitative approach to combine the results of different studies on the same topic, potentially providing more reliable conclusions \[[@B19],[@B20]\]. Considering the extensive role of ACE in the pathogenesis of cancers, a meta-analysis was performed on all eligible case-control studies to estimate the association between this polymorphism and cancer risks.

Methods
=======

Publication search
------------------

We searched literatures in Pubmed database, Embase database, Chinese Biomedical database(CBM) database, Chinese National Knowledge Infrastructure(CNKI) database and Weipu database to identify articles that evaluated the associations between polymorphisms in *ACE*gene and cancer risks(Last search was updated on Aug 31st, 2010). The search terms were used as follows: \'*cancer*or *carcinoma*\' and \'*ACE*or *angiotensin-converting enzyme*\' in combination with \'*polymorphism*or *mutation*or *variant\'*. The languages were limited to English and Chinese. The following inclusion criteria were used in the meta-analysis: (1) the study should evaluate the I/D polymorphism in *ACE*gene and cancer risk, (2) the study should be a case-control design, (3) enough information had to be provided to calculate the odds ratio (OR) with 95% confidence interval (CI), (4) the distribution of genotypes in the control groups should be consistent with Hardy-Weinberg equilibrium (HWE). Accordingly, the following exclusion criteria were also used: (1) abstracts and reviews, (2) studies in which the genotype frequencies were not reported, (3) repeated or overlapped publications. For studies with the same case series by the same authors, the most recently published studies or studies with the largest numbers of subjects were included.

Data extraction
---------------

Data were independently checked and extracted by two investigators. The following items were collected from each study: first author\'s name, year of publication, country of origin, ethnicity, genotyping methods, cancer type, total number of cases and controls, genotype distributions in cases and controls.

Statistical analysis
--------------------

For each case-control study, the HWE of genotypes in the control group was assessed by using Person\'s *X^2^*test. OR and 95% CI was used to assess the strength of the association between the I/D polymorphism and cancer risk. We calculated the OR and respective 95% CI by comparing the carriers of rare alleles with the wild homozygotes (DI+DD vs. II).

Heterogeneity among studies was assessed by a *X^2^*based *Q-*and *I^2^-*statistic. Heterogeneity was considered significant for *P*less than 0.10. The fixed-effects model and random-effects model were used to pool the results. When the *P*value of heterogeneity was greater than 0.10, the fixed-effects model was used, otherwise, the random-effects model was used, as it is more appropriate when heterogeneity is present. The significance of the pooled OR was determined by the *Z*-test and *P*less than 0.05 was considered as statistically significant. To evaluate the ethnicity-specific, cancer type-specific effects, subgroup analyses were performed by ethnic group (\'*European*\', \'*Asian*\', \'*African-American\' and \'Latino\'*) and cancer types. Subgroup analyses by ethnicity were preformed if one ethnic population included more than three case-control studies. Subgroup analysis by cancer type were preformed if one cancer type canteined three and more than three individual studies. Comparisons of other genetic models were also performed (DD vs. DI+II, DD vs. II, DI vs. II and D vs. I).

Publication bias was investigated by using several methods. Visual inspection of asymmetry in funnel plots was carried out. The Begg\'s funnel plots and Egger\'s test were also used to statistically assess publication bias \[[@B21],[@B22]\]. Sensitivity analysis was performed to assess the stability of the results by sequentially excluding each study \[[@B23]\]. All analyses were performed using the software Revman4.2 and STATA 10.0.

Results
=======

Studies selection and characteristics in the meta-analysis
----------------------------------------------------------

There were 486 results relevant to the search words in the selected databases (Figure [1](#F1){ref-type="fig"}). After reading the titles and abstracts, 39 potential articles were included for full-text view. Further screening of these articles, three of them were excluded for being not relevant to cancer risk with *ACE*gene polymorphism. Thus, 36 articles were left for data extraction. Six articles were excluded for not reporting the usable data. One article reported four cohorts each and each cohort was considered as a separate case-control study \[[@B6]\]. Thus, a total of 33 case-control studies in 30 articles were identified. Additionally, 5 case-control studies were excluded for the genotypes in control group not consistent with HWE\[[@B24]-[@B28]\], and 3 case-control studies were excluded for data overlapped or duplicated. Thus, a total of 25 case-control studies in 22 articles were finally identified \[[@B3]-[@B7],[@B9],[@B15]-[@B18],[@B29],[@B14],[@B35]\]. The characteristics of included case-control studies are summarized in Table [1](#T1){ref-type="table"}. Genotype and allele distributions for each case-control study are shown in Table [2](#T2){ref-type="table"}. There were 8 studies of Asians \[[@B4],[@B6],[@B10],[@B11],[@B14],[@B29],[@B30],[@B33]\], 14 of Europeans \[[@B3],[@B5]-[@B7],[@B9],[@B12],[@B13],[@B15]-[@B17],[@B31],[@B32],[@B34],[@B35]\], 2 of Latinos \[[@B6],[@B18]\], 1 of African-Americans \[[@B6]\]. In this meta-analysis, the most studied cancers were lung cancer and breast cancer, the genotype methods are a classic PCR assays

![**Flow diagram of included/excluded studies**.](1471-2350-12-159-1){#F1}

###### 

Characteristics of case-control studies included in meta-analysis

  ------------------------------------------------------------------------------------------------------------------------------------
  Author                          Year   Country       Ethnicity          Cancer type              No.(Cases/Controls)   Genotyping\
                                                                                                                         method
  ------------------------------- ------ ------------- ------------------ ------------------------ --------------------- -------------
  Arima, H\[[@B14]\]              2006   Japan         Asian              Cancers                  176/761               PCR

  Bardi, E\[[@B34]\]              2005   Hungary       European           Cancers                  207/144               PCR

  Cheon, K T\[[@B29]\]            2000   Korea         Asian              Lung                     218/121               PCR

  Ding, × J\[[@B30]\]             2008   China         Asian              Lung                     121/33                PCR

  Goto, Y\[[@B10]\]               2005   Japan         Asian              Gastric                  202/454               PCR

  Haiman, C A(AF)\[[@B6]\]        2003   USA           African-American   Breast                   257/631               PCR

  Haiman, C A(JP)\[[@B6]\]        2003   USA           Asian              Breast                   284/357               PCR

  Haiman, C A(Latinas)\[[@B6]\]   2003   USA           Latino             Breast                   249/652               PCR

  Haiman, C A(Whites)\[[@B6]\]    2003   USA           European           Breast                   292/402               PCR

  Holla, L\[[@B35]\]              1998   Czech         European           Leukemia                 25/202                PCR

  Nacak, M\[[@B3]\]               2010   Turkey        European           Lung                     125/165               PCR

  Nikiteas, N\[[@B16]\]           2007   Greece        European           colorectal               92/102                PCR

  Rocken, C\[[@B7]\]              2005   Germany       European           Gastric                  113/189               PCR

  Rocken, C\[[@B31]\]             2007   Germany       European           Colorectal               141/189               PCR

  Sierra, Diaz E\[[@B18]\]        2009   Mexico        Latino             Prostate                 19/28                 PCR

  Sugimoto, M\[[@B4]\]            2006   Japan         Asian              Gastric                  119/132               PCR

  Toma, M\[[@B13]\]               2009   Romanian      European           Colorectal               108/150               PCR

  Tunny, T J\[[@B17]\]            1996   Australia     European           Aldosterone-producing\   55/80                 PCR
                                                                          adenoma                                        

  Vairaktaris, E\[[@B32]\]        2009   Greece        European           Oral                     160/153               PCR

  van der Knaap, R\[[@B12]\]      2008   Netherlands   European           Colorectal, lung,\       655/6015              PCR
                                                                          breast, prostate                               

  Vaskù, V\[[@B9]\]               2004   Czech         European           T-cell lymphoma          77/203                PCR

  Wang, H W\[[@B11]\]             2000   China         Asian              Lung                     34/38                 PCR

  Yeren, A\[[@B15]\]              2008   Turkey        European           Lung                     75/85                 PCR

  Yigit, B\[[@B5]\]               2007   Turkey        European           Prostate                 48/51                 PCR

  Zhang Q Z\[[@B33]\]             2005   China         Asian              Lung                     47/54                 PCR
  ------------------------------------------------------------------------------------------------------------------------------------

###### 

Distribution of *ACE*genotype and allele among asthma patients and controls

  Author                          Case   Control   Case   Control   HWE for control population                                            
  ------------------------------- ------ --------- ------ --------- ---------------------------- ------ ----- ----- ------ ------ ------- -------
  Arima, H\[[@B14]\]              65     87        24     295       372                          94     217   135   962    560    1.978   0.160
  Bardi, E\[[@B34]\]              74     89        44     52        71                           21     237   177   175    113    0.166   0.683
  Cheon, K T\[[@B29]\]            72     116       30     48        50                           23     260   176   146    96     2.261   0.132
  Ding, × J\[[@B30]\]             55     56        10     19        10                           4      166   76    48     18     1.840   0.175
  Goto, Y\[[@B10]\]               76     98        28     209       189                          56     250   154   607    301    1.674   0.196
  Haiman, C A(AF)\[[@B6]\]        62     118       77     100       310                          221    242   272   510    752    0.254   0.614
  Haiman, C A(JP)\[[@B6]\]        119    128       37     154       160                          43     366   202   468    246    0.021   0.884
  Haiman, C A(Latinas)\[[@B6]\]   73     127       49     189       301                          162    273   225   679    625    3.677   0.055
  Haiman, C A(Whites)\[[@B6]\]    79     129       84     91        187                          124    287   297   369    435    1.613   0.204
  Holla, L\[[@B35]\]              25     11        4      40        86                           76     61    19    166    238    2.937   0.087
  Nacak, M\[[@B3]\]               37     50        38     29        72                           64     124   126   130    200    1.225   0.268
  Nikiteas, N\[[@B16]\]           15     50        27     6         52                           44     80    104   64     140    3.451   0.063
  Rocken, C\[[@B7]\]              24     57        32     41        95                           53     105   121   177    201    0.017   0.898
  Rocken, C\[[@B31]\]             37     69        35     41        95                           53     143   139   177    201    0.017   0.898
  Sierra, Diaz E\[[@B18]\]        0      7         12     9         12                           7      7     31    30     26     0.537   0.464
  Sugimoto, M\[[@B4]\]            54     53        12     50        60                           22     161   77    160    104    0.305   0.581
  Toma, M\[[@B13]\]               25     50        33     30        73                           47     100   116   133    167    0.029   0.864
  Tunny, T J\[[@B17]\]            16     25        14     24        34                           22     57    53    82     78     1.787   0.181
  Vairaktaris, E\[[@B32]\]        30     70        60     9         66                           78     130   190   84     222    1.054   0.305
  van der Knaap, R\[[@B12]\]      141    329       185    1332      3006                         1677   611   699   5670   6360   0.047   0.828
  Vaskù, V\[[@B9]\]               19     37        21     43        103                          57     75    79    189    217    0.078   0.780
  Wang, H W\[[@B11]\]             10     6         18     13        18                           7      26    42    44     32     0.031   0.861
  Yeren, A\[[@B15]\]              4      39        32     14        37                           34     47    103   65     105    0.522   0.470
  Yigit, B\[[@B5]\]               4      19        25     12        24                           15     27    69    48     54     0.157   0.692
  Zhang Q Z\[[@B33]\]             21     21        5      20        30                           4      63    31    70     38     2.567   0.109

Meta-analysis results
---------------------

As shown in Figure [2](#F2){ref-type="fig"}, heterogeneity of DD+DI vs. II for all studies was analyzed and the value of *X^2^*was 79.09 with 24 degrees of freedom and *P*\< 0.00001 in a random-effects model. Additionally, I-square value is another index of the test of heterogeneity. In Figure [2](#F2){ref-type="fig"}, the I-square was 69.7%, suggesting the presence of heterogeneity. Thus, the random-effects model was chosen to synthesize the data. OR was 0.88(95%CI = 0.73-1.06) and the test for overall effect *Z*value was 1.38 (*P*= 0.17). The results suggested that the variant D allele carriers (DI+DD) do not have a significant increased risk of cancer compared with those individuals without D allele (II). Summary of the results of other genetic comparisons are listed in Table [3](#T3){ref-type="table"}.

![**Meta-analysis with a random-effects model for the association between cancer risk and the *ACE*I/D polymorphism (DD+DI vs II)**.](1471-2350-12-159-2){#F2}

###### 

Summary of different comparative results

  Variables                 N    Cases/Controls   DD+DI vs II        DD vs DI+II   DD vs II           D vs I   DI vs II                                                                
  ------------------------- ---- ---------------- ------------------ ------------- ------------------ -------- ------------------- ------ ------------------ ------ ------------------ ------
  Total                     25   3914/11391       0.88(0.73, 1.06)   0.38          0.93(0.80, 1.09)   0.39     0.90(0.73, 1.12)    0.34   0.94(0.83, 1.07)   0.34   0.89(0.75, 1.06)   0.20
  Subgroup by ethnicity                                                                                                                                                                
  Asian                     8    1201/1950        1.13(0.96, 1.33)   0.15          1.05(0.74, 1.49)   0.78     1.09(0.83, 1.44)    0.53   1.08(0.93, 1.25)   0.34   0.85(0.68, 1.06)   0.14
  European                  14   2188/8130        0.89(0.73, 1.09)   0.26          0.89(0.73, 1.09)   0.26     0.76(0.53, 1.08)    0.12   0.86(0.71, 1.03)   0.10   0.78(0.60, 1.01)   0.06
  Subgroup by cancer type                                                                                                                                                              
  Lung                      7    737/6511         1.04(0.70, 1.55)   0.85          0.99(0.67, 1.48)   0.98     1.02(0.62, 1.69)    0.93   1.03(0.80, 1.31)   0.83   1.01(0.64, 1.61)   0.95
  Breast                    5    1235/8057        0.88(0.71, 1.09)   0.24          0.95(0.75, 1.21)   0.70     0.86(0.64, 1.16)    0.33   0.94(0.81, 1.09)   0.41   0.88(0.72, 1.09)   0.24
  Colorectal                4    517/6456         0.81(0.53, 1.24)   0.34          0.83(0.66, 1.05)   0.11     0.73(0.45, 1.18)    0.20   0.87(0.71, 1.06)   0.17   0.87(0.58, 1.31)   0.50
  Gastric                   3    434/775          1.06(0.71, 1.59)   0.78          0.94(0.66, 1.36)   0.76     0.96(0.55, 1.65)    0.87   1.00(0.74, 1.34)   1.00   1.12(0.79, 1.58)   0.52
  Prostate                  3    276/6094         2.44(0.66, 8.97)   0.18          2.05(0.74, 5.62)   0.17     3.48(0.63, 19.13)   0.15   2.05(0.84, 5.02)   0.11   1.66(0.67, 4.07)   0.27

\*: P value for Q-test.

Subgroup analyses were performed after stratifications of the data by ethnicity and cancer types. In the subgroup analysis by ethnicity (Figure [3](#F3){ref-type="fig"}), no significant increased risks were found in *Europeans*and *Asians*. In the subgroup analysis by cancer types (Figure [4](#F4){ref-type="fig"}), no significant increased risk was found in lung cancer, breast cancer, colorectal cancer, gastric cancer, prostate cancer. Thus, the polymorphism may not increase cancer risk in different population and different cancers.
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![**Meta-analysis with a random-effects model for the association between cancer risk and the *ACE*I/D polymorphism (DD+DI vs II): subgroup analysis by cancer type**.](1471-2350-12-159-4){#F4}

Publication bias
----------------

Begg\'s funnel plot and Egger\'s test were performed to assess the publication bias of the literatures. The shape of the funnel plots seemed approximately symmetrical (DD+DI vs. II) and the Egger\'s test did not show any evidence of publication bias (*t*= 0.45 and *P*= 0.655 for DD+DI vs. II) (Figure [5](#F5){ref-type="fig"}).

![**Begg\'s funnel plot for publication bias in selection of studies on the *ACE*I/D polymorphism (DD+DI vs II)**.](1471-2350-12-159-5){#F5}

Sensitivity analysis
--------------------

Sensitivity analysis was analyzed as previous study \[[@B23]\]. Briefly, after excluding each case-control study for DD+DI vs. II comparative (Table [4](#T4){ref-type="table"}), statistically similar results were obtained, suggesting the results of this meta-analysis are stable.

###### 

Sensitivity analysis for the current meta-analysis: ORs with 95%CIs and P value were results after excluding each case-control study for DD+DI vs.II.

  Author                          OR     95%CT       P
  ------------------------------- ------ ----------- ------
  Arima, H\[[@B14]\]              0.87   0.71-1.06   0.16
  Bardi, E\[[@B34]\]              0.87   0.72-1.06   0.16
  Cheon, K T\[[@B29]\]            0.86   0.71-1.04   0.12
  Ding, × J\[[@B30]\]             0.86   0.71-1.04   0.12
  Goto, Y\[[@B10]\]               0.85   0.71-1.03   0.10
  Haiman, C A(AF)\[[@B6]\]        0.90   0.74-1.09   0.27
  Haiman, C A(JP)\[[@B6]\]        0.87   0.71-1.06   0.16
  Haiman, C A(Latinas)\[[@B6]\]   0.87   0.71-1.06   0.17
  Haiman, C A(Whites)\[[@B6]\]    0.88   0.78-1.07   0.21
  Holla, L\[[@B35]\]              0.93   0.79-1.09   0.38
  Nacak, M\[[@B3]\]               0.90   0.75-1.09   0.27
  Nikiteas, N\[[@B16]\]           0.90   0.75-1.08   0.26
  Rocken, C\[[@B7]\]              0.87   0.72-1.06   0.16
  Rocken, C\[[@B31]\]             0.88   0.73-1.07   0.21
  Sierra, Diaz E\[[@B18]\]        0.87   0.72-1.04   0.13
  Sugimoto, M\[[@B4]\]            0.89   0.73-1.07   0.22
  Toma, M\[[@B13]\]               0.88   0.73-1.07   0.19
  Tunny, T J\[[@B17]\]            0.87   0.72-1.06   0.16
  Vairaktaris, E\[[@B32]\]        0.91   0.76-1.09   0.31
  van der Knaap, R\[[@B12]\]      0.87   0.71-1.07   0.18
  Vaskù, V\[[@B9]\]               0.88   0.73-1.07   0.19
  Wang, H W\[[@B11]\]             0.87   0.72-1.05   0.15
  Yeren, A\[[@B15]\]              0.86   0.71-1.03   0.10
  Yigit, B\[[@B5]\]               0.86   0.71-1.03   0.10
  Zhang Q Z\[[@B33]\]             0.88   0.73-1.07   0.20

Discussion
==========

ACE is a key enzyme in the renin-angiotensin system, which is involved in the regulation of blood pressure and serum electrolytes. In recent years, more evidences indicated that the enzyme was associated with the pathogenesis of cancers. It may influence tumor cell proliferation, migration, angiogenesis and metastatic behaviors. Given the important roles of ACE in cancer etiology, it is possible that genetic variations of the *ACE*gene may modulate the risk of cancer. The I/D polymorphism in intron 16 of the *ACE*gene is the most extensively studied polymorphism. This polymorphism is based on insertion or deletion of a 287-bp Alu sequence, leading to a change in the plasma ACE level. Growing number of studies have been published to investigate the associations between this polymorphism with cancer risk; however, the results were inconsistent and conflict. In order to resolve this issue, we conducted a meta-analysis of 25 case-control studies, including 3914 cases and 11391 controls, to evaluate the associations between the *ACE*I/D polymorphism and cancer risks.

Our results showed that the *ACE*I/D polymorphism was not associated with cancer risks. Moreover, in other comparative genetic models, no significant associations were found in any genetic models. These results indicated that this polymorphism may not contribute to cancer risks. Although previous studies revealed possible roles of ACE in cancer etiology, our result suggested that these roles may not account by the variant of *ACE*gene. Although the exact mechanism of this enzyme in cancer etiology is not so clear, our results may indicate that ACE I/D polymorphism may not influence cancer risk. In addition, considering the possible role of this polymorphism in serum ACE level, it is possible that the cancer risk may be modified by ACE level, but not by the variant. Thus, future studies are warranted to identify the associations between *ACE*polymorphism, ACE levels and cancer risk.

Considering the property of genetic background may affect the results of genetic association studies, we performed subgroup analysis by ethnicity. Two subgroups were included in this meta-analysis: \'European\' and \'Asian\'. In this meta-analysis, we didn\'t find a significant association between this polymorphism and cancer risk in any sub-populations. Moreover, no significant associations were found in any other genetic models. Interestingly, this polymorphism and cancer risk in Asians and Europeans were all inversely associated, although they were not statistically significant. These results may suggest that this polymorphism may exert varying effects in different populations. However, all included studies were from European, Asian, African-American and Latino populations, further studies are necessary to validate these findings for other ethnic populations, especially in Africans.

In another subgroup analysis by cancer types, we found that this polymorphism is not associated with increased risks in all sub-cancer types (lung, breast, prostate, gastric and colorectal). Considering the limitation of studies in each subgroup, the weak associations between this polymorphism and different cancers should be discussed. It is possible that these null associations may be due to chance because studies with small sample size may have insufficient statistical power to detect a slight effect. Considering the limited studies in each cancer type, our results should be explained with caution.

Heterogeneity is one of the important issues when performing meta-analysis. We found that heterogeneity between studies existed in overall comparisons. After subgroup analysis by ethnicity and cancer types, the heterogeneity was effectively decreased or removed in Asians and some cancer types, suggesting that certain effects of genetic variants are cancer specific and ethnic specific. The stability of this meta-analysis was analyzed by sequentially excluding individual studies; our results indicated stability of results. Publication bias is another important issue which should also be discussed in meta-analysis. After evaluating the publication bias by Egger\'s funnel plots and Begg\'s test, we did not detect a publication bias, indicating the strength of the results.

Cancers have been considered as genetic diseases, and many genetic variants are contributed to cancer risks \[[@B36]-[@B40]\]. It is worthy to mention the recently studies of genetic analysis by genome wide-association studies (GWAS). Up to now, a large number of GWAS for cancers have been published, and a large number of cancer susceptible loci were found \[[@B36]-[@B38],[@B41]-[@B46]\]. However, none of them indicated the *ACE*D/I polymorphism, which can be partly explained by the chips which were used in the original studies. There is probably a lack of adequate coverage on chips which also identify insertion or deletion a 287-bp sequence. It is noted worthy, the SNP rs4343, which is considered as a good proxy in Caucasians for I/D variant (r2 \> 0.80), have been studied by Illumina genotyping arrays \[[@B47],[@B48]\]. Thus, further studies may investigate rs4343 for cancer risk by GWAS to help to resolve whether the I/D polymorphism is associated with cancer risk.

We have to mention a recently published study by Ruiter in 2011\[[@B49]\]. They also investigated the ACE I/D polymorphism with the risk of cancers. There were some differences between these two studies. First, the current meta-analysis included more case-control studies than Ruiter\'s study. Second, some issues which may affect the results of meta-analysis were addressed in our study, such as publication bias, sensitivity analysis and HWE analysis. Third, the current study is a meta-analysis, and Ruiter\'s study is more like a review. Despite of these differences, our study also indicated the ACE I/D polymorphism might not contribute to the risk of cancer, which is consistent with Ruiter\'s study.

Some limitations of this study should be addressed. First, only published studies in Chinese and English which were included by the selected databases were included for data analysis, some potential studies which were included by other databases or published with other languages or unpublished could be missed. Second, due to lack of original data, we could not evaluate the potential interactions of gene-gene and gene-environment. Third, this meta-analysis included data from Europeans, Asians, African-American and Latino populations, so that, the results are applicable to only these ethnic groups. Fourth, it is reported that PCR amplification of ACE I/D polymorphism using only flanking primer pairs would misclassify 4-5% of the ID genotype as the DD genotype and a second PCR should performed to confirm the DD genotype\[[@B50]\]. However, only a small portion of included studies performed a second PCR, indicating the possibility of imprecise results of the meta-analysis. Fifth, some other important factors may also bias our results, such as smoking status, the heterogeneity of cancer patients (pre- or post -menopausal breast cancer patients); genotyping technique changes over time and other unknown function of RAS system et al. However, this meta-analysis also has some advantages. First, the comprehensive meta-analysis included more than 15,000 individuals; it is statistically more powerful than any single study. Second, this is a comprehensive meta-analysis concerning cancer risk and *ACE*D/I polymorphism and the result also indicated a gene in RAS may not contribute to cancer risk. Third, the result of publication bias is not significant; indicating the conclusion of this study may be unbiased.

In summary, this meta-analysis suggests that the I/D polymorphism in the *ACE*gene may not contribute to susceptibility to cancer. However, larger well-designed studies are warranted to validate these findings. Moreover, future studies should also investigate gene-gene and gene-environment interactions to better display the association between the polymorphisms in *ACE*gene and cancer risk.

Conclusion
==========

These results suggest that the D/I polymorphism in *ACE*gene may not contribute to susceptibility to cancer.
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